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Unfortunately, the original version of this article [1] 
contained errors in the main text and in Tables 2 and 3. 
Tables  2 and 3 were included incorrectly. The correct 
Tables 2 and 3 have been updated in the original article 
and are also included correctly in this erratum.
Additionally, the following section has been corrected:
However, after adjustment MBL for these confounders 
levels remained associated with cardiovascular events, 
indicating a direct and independent effect of MBL on car-
diovascular risk.
Should read:
However, after adjustment for these confounders, MBL 
levels remained associated with cardiovascular events, 
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Table 2 Baseline characteristics of hemodialysis patients presented as groups according to MBL levels
Patients P* < 0.001 R P#
All (n = 107) MBL low 319 < ng/mL 
(n = 26)
MBL high 319 ≥ ng/mL 
(n = 81)
MBL range (ng/mL) 821 [319–1477] 98 [33–146] 1290 [671–1848]
Demographics
Age, years 62.5 ± 15.6 65.3 ± 12.1 61.56 ± 16.6 0.3 −0.26 0.007
Male gender, n (%) 71 (66) 17 (65) 54 (67) 1.0
Current diabetes, n (%) 25 (24) 9 (35) 16 (20) 0.2
Hypertension, n (%) 85 (84) 22 (88) 63 (83) 0.8
Cardiovascular history, n (%) 26 (25) 9 (35) 15 (19) 0.1
BMI, kg/m2 25.8 ± 4.4 27.0 ± 4.5 25.4 ± 4.4 0.1 −0.03 0.8
Hemodialysis
Dialysis vintage, months 25.5 [8.5–52.3] 18.2 [7.0–47.7] 32.8 [9.1–53.3] 0.2 −0.01 0.9
Primary renal disease, n (%)
Hypertension 18 (17) 4 (15) 14 (17) 1.0
Diabetes 14 (13) 5 (19) 9 (11) 0.3
ADPKD 13 (12) 3 (12) 10 (12) 1.0
FSGS 9 (8) 4 (15) 5 (6) 0.2
IgA nephropathy 4 (4) 0 (0) 4 (5) 0.6
Chronic pyelonephritis 3 (3) 0 (0) 3 (4) 1.0
Glomerulonephritis 13 (12) 2 (8) 11 (14) 0.7
Other diagnoses 16 (16) 6 (23) 10 (12) 0.2
Unknown 17 (16) 2 (8) 15 (19) 0.2
Ultrafiltration volume, L 2.55 ± 0.78 2.54 ± 0.82 2.56 ± 0.78 0.9 −0.01 0.9
Ultrafiltration rate, mL/kg/h 8.56 ± 2.63 7.81 ± 2.39 8.80 ± 2.67 0.1 0.04 0.7
Systolic blood pressure
Predialysis, mmHg 140.4 ± 25.1 144.7 ± 26.4 139.1 ± 24.7 0.3 −0.17 0.08
Postdialysis, mmHg 131.8 ± 25.6 136 ± 24.3 130.4 ± 26.0 0.4 −0.24 0.02
Heart rate
Predialysis, bpm 73 [63–82] 71 [62–82] 74 [64–82] 0.3 0.11 0.3
Postdialysis, bpm 79 [69–87] 75 [65–86] 79 [69–88] 0.4 0.13 0.2
Kidney transplant, n (%) 21 (20) 4 (15) 17 (21) 0.8
Laboratory measurements
Hematocrit, % 34.9 ± 3.8 34.5 ± 4.1 35.0 ± 3.7 0.6 0.04 0.7
HbAlc, mmol/mol 5.68 ± 0.98 5.80 ± 0.97 5.63 ± 0.98 0.5 −0.15 0.2
Albumin, g/L 39 [37–42] 39 [37–42] 39 [37–42] 0.9 0.01 0.9
pH 7.37 [7.34–7.39] 7.37 [7.32–7.39] 7.37 [7.34–7.39] 0.7 0.05 0.6
Calcium, mmol/L 2.31 ± 0.16 2.31 ± 0.15 2.32 ± 0.16 0.9 0.03 0.7
Phosphate, mmol/L 1.67 ± 0.53 1.82 ± 0.47 1.65 ± 0.54 0.2 −0.00 0.9
hsCRP, mg/L 6.7 [2.8–10.9] 6.1 [1.4–12.0] 6.7 [3.0–10.9] 0.7 0.10 0.3
Medication
Aspirin, n (%) 57 (54) 11 (42) 46 (64) 0.3
Calcium channel blockers, n (%) 14 (13) 3 (12) 11 (14) 1.0
β‑Blocker, n (%) 61 (57) 18 (69) 43 (53) 0.2
ACE inhibitor, n (%) 10 (10) 3 (12) 7 (9) 0.7
AT2‑receptor antagonists, n (%) 14 (13) 2 (8) 12 (15) 0.5
Statin, n (%) 20 (19) 5 (19) 15 (19) 1.0
Diuretics, n (%) 8 (8) 3 (12) 5 (6) 0.4
Italic values used to show which statistical testing was significant (below 0.05)
Data are presented as mean ± SD or median [IQR]
BMI body mass index, ADPKD autosomal dominant polycystic kidney disease, FSGS focal segmental glomerulosclerosis, HDA1c hemoglobin A1c, pH potential 
hydrogen, hsCRP high sensitive C-relative protein, ACE inhibitor angiotensin-converting-enzyme inhibitor, AT2 receptor antagonists Angiotensin II receptor antagonists
P* indicates P value for the difference in baseline characteristics between the MBL groups, tested by Student’s t test or Mann–Whitney U test for continuous 
variables and with χ2 test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; P# indicates the 
corresponding P value
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Table 3 Associations of MBL levels with cardiovascular events and cardiac events in 107 chronic hemodialysis patients
Model 1: crude
Model 2: adjusted for age and gender
Model 3: adjusted for model 2 plus ultrafiltration volume and dialysis vintage
Model 4: adjusted for model 3 plus cardiovascular history, diabetes and post-HD systolic blood pressure
Model 5: adjusted for model 4 plus hsCRP
Data are presented as hazard ratio (HR) plus 95 % confidence interval (CI) according to the cut-off of MBL and per standard deviation (SD) MBL increase
Italic values used to show which statistical testing was significant (below 0.05)
MBL mannose-binding lectin, HD hemodialysis, hsCRP high sensitive C-reactive protein
Low MBL Log MBL continuous
HR 95 % CI P HR (per SD) 95 % CI P
Cardiovascular events
 Model 1 2.64 1.36–5.13 0.004 0.64 0.46–0.90 0.01
 Model 2 2.75 1.39–5.44 0.004 0.61 0.43–0.88 0.008
 Model 3 2.94 1.45–5.94 0.003 0.61 0.42–0.89 0.01
 Model 4 3.55 1.70–7.40 0.001 0.58 0.40–0.84 0.004
 Model 5 3.98 1.88–8.42 <0.001 0.56 0.38–0.81 0.002
Cardiac events
 Model 1 2.60 1.10–6.18 0.03 0.71 0.46–1.10 0.1
 Model 2 2.49 1.04–5.96 0.04 0.73 0.46–1.16 0.2
 Model 3 2.65 1.08–6.55 0.03 0.74 0.47–1.18 0.2
 Model 4 3.82 1.48–9.87 0.006 0.62 0.38–1.01 0.06
 Model 5 3.96 1.49–10.54 0.006 0.59 0.35–0.98 0.04
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